Panobinostat
- TRADE NAME: Farydak (Novartis)
- INDICATIONS: Multiple myeloma (in combination with bortezomib and dexamethasone)
- CLASS: Histone deacetylase (HDAC) inhibitor
- HALF-LIFE: 37 hours
FDA APPROVAL DATE: 02/23/2015
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Antiarrhythmics, QT prolonging agents, Sensitive CYP2D6 substrates, Strong CYP3A4 inducers
PREGNANCY CATEGORY: N/A
can cause fetal harm
FATAL AND SERIOUS TOXICITIES: SEVERE DIARRHEA AND CARDIAC TOXICITIES
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric